We are incredibly disappointed with NICE’s announcement today that abemaciclib with fulvestrant, a treatment for certain people with secondary breast cancer, has been provisionally rejected for routine use on the NHS. breastcancernow.org/about-us/media/statements/we-respond-draft-nice-decision-not-recommend-abemaciclib-fulvestrant-routine-use-nhs?utm_source=forumo&utm_medium=website&utm_campaign=campaign&utm_content=120221niceresponse
Patients currently receiving this treatment will not be affected by this decision, however unless this draft decision is reversed, it will not remain an option for new secondary breast cancer patients in the future.
We are calling on NICE, drug manufacturer Lilly UK, and NHS England to work together to explore every possible solution to ensure this treatment can remain available on the NHS.
NICE has launched a consultation on this decision. We urgently need your help to make a compelling argument to NICE about the importance of keeping abemaciclib with fulvestrant available. If you have received this treatment and are happy to share your experience of having this treatment, please email the Campaigns team on campaigns@breastcancernow.org.